Sidoti Csr Estimates Kamada’s Q2 Earnings (NASDAQ:KMDA)

Kamada Ltd. (NASDAQ:KMDA) – Analysts at Sidoti Csr lifted their Q2 2025 earnings per share estimates for Kamada in a report released on Monday, March 3rd. Sidoti Csr analyst J. Sidoti now anticipates that the biotechnology company will post earnings per share of $0.08 for the quarter, up from their prior estimate of $0.07. The consensus estimate for Kamada’s current full-year earnings is $0.23 per share. Sidoti Csr also issued estimates for Kamada’s Q3 2025 earnings at $0.08 EPS.

Separately, HC Wainwright reissued a “buy” rating and set a $11.00 target price on shares of Kamada in a report on Friday, January 10th.

Kamada Stock Performance

KMDA opened at $6.61 on Tuesday. Kamada has a fifty-two week low of $4.74 and a fifty-two week high of $9.15. The company has a market capitalization of $379.94 million, a P/E ratio of 23.61, a P/E/G ratio of 0.97 and a beta of 0.99. The stock has a fifty day moving average of $7.04 and a 200-day moving average of $6.13.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of KMDA. Plato Investment Management Ltd acquired a new position in Kamada in the third quarter valued at about $117,000. Public Employees Retirement System of Ohio acquired a new position in Kamada in the third quarter valued at about $77,000. JPMorgan Chase & Co. acquired a new position in Kamada in the fourth quarter valued at about $67,000. NewEdge Advisors LLC raised its stake in Kamada by 54.2% in the fourth quarter. NewEdge Advisors LLC now owns 23,496 shares of the biotechnology company’s stock valued at $143,000 after purchasing an additional 8,260 shares in the last quarter. Finally, Aristides Capital LLC raised its stake in Kamada by 12.1% in the fourth quarter. Aristides Capital LLC now owns 63,485 shares of the biotechnology company’s stock valued at $387,000 after purchasing an additional 6,850 shares in the last quarter. Institutional investors and hedge funds own 20.38% of the company’s stock.

About Kamada

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.